Archean Chemical Industries

Investment case

Bromine cost-curve leader

Why this business

Archean Chemical is India's largest producer of bromine and industrial salt from brine at Hajipir, Gujarat (Rann of Kutch), with ~78% of revenue exported; FY26 revenue Rs 1,108 cr split industrial salt Rs 729 cr and bromine Rs 308 cr. It is building sulphate of potash (SOP), bromine derivatives (Acume, EBITDA-positive for the first time in Q1FY27), zinc-bromide energy storage, and a USD 250 mn silicon-carbide semiconductor fab/packaging unit (SiCSem, Odisha; 60,000 wafers and 96 mn packaging units/yr; partners Clas-SiC UK, Aixtron, IIT Bhubaneswar) approved under the India Semiconductor Mission.

What we believe

1. 01Bromine cycle turning after three weak years: Q1FY27 bromine realisations +50% YoY, volumes at a five-quarter high; China bromine +35% in Q1CY26 to ~USD 4,900/t (Jun-2026) before easing to USD 4,347/t (Jul-2026) - still far above the 2024-25 trough.
2. 02Operating leverage on a low base: FY26 EBITDA Rs 239 cr (22% margin) vs Rs 463 cr (35%) in FY24; ICICI Sec sees >50% EBITDA CAGR FY26-28 as bromine run-rate rises to 20-24 kt and freight/fuel costs stabilise.
3. 03New products moving from cost to profit: Acume bromine derivatives EBITDA-positive for the first time in Q1FY27 (Rs 1.9 cr vs Rs -2.7 cr), SOP phase-2 trials by Q3FY27, zinc-bromide off-grid storage.
4. 04Optionality in SiC semiconductors: USD 250 mn SiCSem fab in Odisha under ISM fiscal support (agreement 11-May-2026), 60,000 wafers/yr, revenue from FY29 - not in broker estimates.
5. 05Low leverage and export-led: borrowings Rs 466 cr vs equity Rs 1,935 cr; ~78% exports; working-capital days improved from 49.5 to 10.8.

Why now

63.6x TTM PE reflects trough earnings (FY26 PAT Rs 105 cr vs Rs 319 cr in FY24); P/B 3.2x (499/157). Stock -27% over 1 year and 3-yr profit CAGR -35%; Buoyant 34.6x FY28e vs ICICI Sec 16x FY28E EBITDA. EV/EBITDA n.m.; dividend yield 0.5%.

Market disagreement

• Tata Chemicals: Tata Chemicals posted a Rs 1,715 cr FY26 loss, ROE 1.3%, Rs 8,001 cr debt and Q1FY27 PAT -81%; soda-ash oversupply from China is structural, whereas Archean's bromine is recovering with a clean balance sheet.
• GHCL: GHCL is cheap (8.8x, 2.75% yield, ROE 13%, net debt ~nil) but is a soda-ash commodity play with Q1FY27 sales/profit -4% and promoter holding of only 19.8%; Archean offers higher growth (ICICI Sec >50% EBITDA CAGR) and 53% promoter skin-in-the-game.

Position sizing

Cyclical Small cap  0.6% of the PMS on $31 Jul 2026 (August rank not in top 30). Satellite positions are owned for an asymmetry, sized up when the cycle rewards risk and reduced when it does not.

Catalysts

• Q2FY27 results (Nov-2026): bromine volume run-rate progressing toward 20-24 kt and salt pricing stabilisation guided for H2FY27.
• SOP phase-2 commissioning by Q3FY27 and continued Acume derivatives profitability.
• SiCSem fab milestones (equipment orders with Aixtron, Clas-SiC integration) and any ISM disbursement news.

Risks and response

• Bromine price volatility: prices already fell 11% QoQ in Jul-2026 as Chinese supply recovered; FY26 bromine revenue fell 13% and Q4FY26 had technical downtime.
• Capital intensity and execution: borrowings up from Rs 98 cr (FY24) to Rs 466 cr (FY26) funding SOP, derivatives and the USD 250 mn SiC fab - a technology the company has no track record in; interest/depreciation already dragged Q1FY27 PAT -25%.
• Salt business (66% of FY26 revenue) faces weak pricing and freight sensitivity; ROE only 5.4% in FY26 (3-yr 11%).

Thesis-break conditions

Not stated separately on this page; the risk list carries the monitoring triggers.

Review history

• 8 Sep 2026 · Yash Palod · one-pager in "Why We Own What We Own" (p66) · portfolio as of $31 Jul 2026
• 31 Aug 2026 · Classification in the August top-30: —

Source: Buoyant_Why_We_Own_What_We_Own_Sep2026.pdf (portfolio as of 31 July 2026), p66. Internal; external publication of these fields is controlled by audience policy.